The global allergy immunotherapy sales is valued at USD 1,942.1 million in 2025, registering Y-o-Y growth of 7.9% attaining market value of USD 4,161.9 million by 2035. The revenue generated by allergy immunotherapy in 2024 was USD 1,840.8 million.
The future of the allergy immunotherapy market is promising, with rising allergy incidence across worldwide, further increasing awareness and advancements in treatment modalities among different demography of patients. The market is expected to witness robust growth driven by a shift toward personalized medicine and the introduction of innovative therapies which includes biologics and peptide-based immunotherapy.
Pharmaceutical manufacturers are investing significantly in next-generation sublingual immunotherapy drugs which are also known as SLIT to enhance efficacy and patient compliance. Multiple players that are now actively expanding their product portfolios through successful clinical trials.
Several new immunotherapy drugs are in late stage pipeline and are expected to get regulatory approval in the next few years. Integration of AI into drug development has accelerated the discovery of novel allergens and is filtering treatment protocols. Moreover, improvements in recombinant allergen-based immunotherapy are going to improve the safety and reduce the duration of treatment.
Strategic alliances and acquisitions between biotechnology companies and pharmaceutical majors will further drive the market forward. As patient preference shifts toward convenient and effective therapies, the allergy immunotherapy landscape will continue to evolve, providing wider access to cutting-edge treatments and better disease management worldwide.
Global Allergy Immunotherapy Industry Analysis
| Metric | Values |
|---|---|
| Industry Size (2025E) | USD 1,942.1 million |
| Industry Value (2035F) | USD 4,161.9 million |
| CAGR (2025 to 2035) | 7.9% |
Manufacture of oral immunotherapy products currently gains the major focus of manufacturers. Oral immunotherapies are mainly in focus for hay fever and food allergy. Oral immunotherapy is an effective approach in inducing desensitization in food allergic individuals, and represents a valid therapeutic option for peanut, cow's milk, and egg allergic patients.
OIT can potentially decrease the risk for severe allergic reactions due to accidental or unintentional allergen exposures for individuals who tolerate this process. Food allergy OIT involves giving food allergens under medical supervision, initially in small amounts, then gradually increasing amounts, followed by continued daily consumption of the food allergen.
Similarly, the development of interest regarding personalized treatment in the target is driving the market significantly. As a result, research and development regarding personalized treatments are considered an emerging trend of the market.
The molecular understanding of allergic diseases is gaining new dimensions. Regarding this, new and advanced kinds of personalized treatment are being elaborated by the researchers and the clinicians for addressing the unique treatment needs of respective patients.
This is therefore the trend which fuels biomarkers and diagnostics development to identify the real causes of allergy and inform treatment decisions.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
A comparative analysis of fluctuations in compound annual growth rate (CAGR) for the allergy immunotherapy industry outlook between 2024 and 2025 on a six-month basis is shown below.
By this examination, major variations in the performance of these markets are brought to light, and trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market’s growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December.
The table below compares the compound annual growth rate (CAGR) for the global allergy immunotherapy market from 2024 to 2025 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
While H1 runs from January to June, H2 starts from July to December. It is estimated that the business, in the first half of 2024 to 2034, will surge upward at a growth rate of 8.1% CAGR, while from the second half of the decade, it may grow at 8.5%.
| Particular | Value CAGR |
|---|---|
| H1 | 8.1% (2024 to 2034) |
| H2 | 8.5% (2024 to 2034) |
| H1 | 7.9% (2025 to 2035) |
| H2 | 8.4% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 7.9% in the first half and projected to lower at 8.4% in the second half. In the first half (H1) the market witnessed a decrease of 20 BPS while in the second half (H2), the market witnessed a decrease of 16 BPS.
Changing Lifestyle and Adoption of Urbanized Culture is leading the Market Growth for Allergy Immunotherapy
Growing cases of allergic disorders is increasing the need of more specific and convenient treatments, which is in turn driving the market for allergy immunotherapy across the globe. Changing lifestyle and adoption of urbanized culture is leading to cause new allergic disorders.
Hence, the changing lifestyle can increase the need for allergy immunotherapy treatments and help to drive the market growth Strong focus and continuous investments in research and technological advancement by key players for the development and commercialization of allergy immunotherapy products are expected to rise, leading to present more advanced and specific treatment options. Allergy immunotherapy industry is witnessing continuous innovations in terms of specific treatments, recombinant immunotherapies, among others.
Manufacturers in this industry are after extending their portfolio, customer base and geographic reach through M&A, collaboration/partnerships. This help the players to form mutual growth and maintain the competitive edge, and fulfil customer needs.
The increasing popularity of subcutaneous immunotherapy (SCIT) generates a unique trend in the market.
SCIT is an unique therapy among those for allergic disease, as it provides symptomatic relief and modifies the allergic disease by acting on the underlying immunological mechanism simultaneously.
SCIT is used when the symptoms are chronic, difficult to control and affect one's daily life. Symptoms targeted by the SCIT in general are an aim to reduce symptoms of allergic rhinitis and or asthma and the need for medications.
It is administered in conjunction, though the requirements for nasal sprays and or antihistamines must diminish with time since the immunotherapy starts taking an effect. It is also provided for individuals that experience anaphylaxis by a bee, wasp and jack jumper ant.
Immunotherapy is not part of routine clinical practice either in food allergy or eczema. Subcutaneous immunotherapy is presently the most popular and effective form of allergy immunotherapy; it represents the only treatment that effectively alters the immune system by preventing the emergence of new allergies and asthma.
SCIT represents the standard procedure in patients with sensitizations against aeroallergens. SCIT is one of the few new therapies of allergic diseases; besides its benefit in terms of alleviation of suffering, allergic disease modification exists due to intervention in the basic immunological process. In controlled clinical studies in asthma, allergic rhinitis/rhinoconjunctivitis, and hypersensitivity due to stinging insects, SCIT demonstrated efficacy and safety.
Thus, adoption of subcutaneous immunotherapy is increasing which propels the growth for allergy immunotherapy market.
Increase In the Number of Research and Development Activities for Patient Centered Treatments Opens Market Opportunities
A rise in the number of R&D activities is another factor driving the market's expansion. This will present advantageous chances for the expansion of the market for allergy treatments. Coupled with this, an increase patient centric treatment approach is evolving over the globe. Recombinant allergy vaccines are developed considering the individual patient centric need and hence can show effective results.
In 2020 the FSA launched a range of research projects relating to Food Hypersensitivity. As part of this work, Allergy UK is involved in a collaborative piece, led by Aston University, called the Foodsensitive study, looking at quality of life and other impacts of food allergy Current research is investigating the effect of the environment in which we live, on genetic factors.
It is now clear that many genes can be ‘turned on or off’ by environmental factors. For example, viral infections are able to modulate our immune systems by switching certain genes on or off, promoting an allergic tendency in immune cells.
Also, growing investments in the development of cutting-edge technologies and an increase in the number of new markets will create more favourable conditions for the expansion of the allergy treatment market throughout the course of the forecast year.
Experiencing of Adverse-Effects of the Treatment and High Upfront Costs Pose Market Challenges
Allergy immunotherapy is a lengthy treatment and may continue up to 3 to 5 years depending upon the type and stage of allergy.
Patients undergoing the treatment usually discontinue the process halfway because of the prolonged treatment time, age, health, physical location and budget constraints.
This can negatively impact the market growth. The market is experiencing a drop due to the adverse effects linked with allergy shots and tablets. For instance, more than 1.5% of the patients administering Oralair experience adverse effects such as respiratory, gastrointestinal or skin related disorders.
Along with that, patients can experience minor effects such as redness or swelling at the injection site or effects on entire body or particular body system. Additionally, rarely a serious systemic reaction called anaphylaxis can develop. The adverse and side effects linked with the treatment may regress the market growth.
The allergy immunotherapy is prolonged process and hence cost associated with it also becomes a burden for patients. Allergy shots treatment can cost USD 1000, SLIT costs ~USD 7000, and oral therapy (Palforzia) can cost ~USD 4000 per year, if not covered under insurance.
Along with that, there can be a possibility that, a patient can be treated with combination therapy which will certainly increase the cost. Thus high cost of the treatment can limit the market growth.
The global allergy immunotherapy industry recorded a CAGR of 3.6% during the historical period between 2020 and 2024. The growth of the allergy immunotherapy diagnostics industry was positive as it reached a value of USD 1,840.8 million in 2024 from USD 1,597.1 million in 2020.
The market for allergy immunotherapy, has demonstrated considerable growth lately due to a rise in prevalence related to the allergic diseases-like allergic rhinitis, asthma, and food allergies. Also, increasing levels of pollution and changing lifestyles as well as further awareness of such allergic conditions act as contributors for the rise in demand for some effective long-time treatments.
Traditional pharmacological treatments were primarily symptom-oriented and included medications like antihistamines and corticosteroids. In that respect, there's been a shift in favor of allergy immunotherapy for treatment by the modification of the immune response and long-term benefits it offers.
SLIT is preferred for its ease of administration, low risk of severe reactions, and better patient compliance. As a result, developments in the area have been represented by the increasing application of sublingual immunotherapy as a complement to conventional subcutaneous immunotherapy.
On the other hand, the recent advent of biotechnology has opened routes for more precise and standardized allergen extracts, which have enhanced the efficacy and safety profile of immunotherapeutic interventions importantly.
Hence, various pharmaceutical companies, while developing novel formulations, have emphasized peptide-based vaccines and recombinant allergen immunotherapy for better results in treatment.
The market is very likely to go upwards because investments in research and development continue to rise, as do approvals from regulatory agencies of new therapies; the concept of personalized medicine has also started taking a greater foothold.
Improved molecular diagnostics will also facilitate enhancements in immunotherapy by permitting highly specific treatments based on each particular patient. Due to ongoing clinical trials and the expansion of immunotherapy applications beyond respiratory allergies to food and venom allergies, the market is likely to undergo significant transformation in the next few years.
Tier 1 players in this market holds 34.1%. In the tier 1 are companies with a significant global presence, such as ALK Abello, Stallergenes Greer, and Allergy Therapeutics. They dominate the market through extensive product pipelines, strategic collaborations, and advanced biotechnology in immunotherapy. These companies are responsible for pioneering innovations, large-scale production, and regulatory influence in the industry.
In the tier 2, companies like BioLight Technologies LLC, THOR Photomedicine Ltd, Irradia are prominent players that occupies around 23.6% market share with a solid presence in specific regional markets. Tier 2 players are typically regional or mid-sized companies that compete in specific markets with a more localized focus.
While they may not have the same global reach or financial power as Tier 1 players, they often excel in niche markets, cost-effective production, or regional dominance. Many of these companies collaborate with research institutions and larger firms for advanced product development.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below covers the allergy immunotherapy industry analysis for the sales for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 3.8% through 2035. In South Asia & Pacific, India is projected to witness the highest CAGR in the market of 6.1% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 8.1% |
| UK | 8.3% |
| Germany | 7.4% |
| Japan | 7.9% |
| India | 9.2% |
| China | 9.6% |
The United States dominates the global market with a maximum share in 2024. The market exhibits a CAGR of 8.1% over the forecast period 2025 to 2035.
The USA allergy immunotherapy market has been dominated by injections-only modality-SCIT because it has a physician-controlled treatment model with structured reimbursement.
To date, SCIT remains the gold standard in the USA, with allergists giving injections to their patients in-office. Also, the public awareness regarding the quick action of injectables are forcing the healthcare professional to align with trend, as a result the demand for injectables is rising.
There are very few SLIT tablets approved in the USA, covering just a few allergens such as grass, ragweed, and dust mites. The insurance model in the United States also supports SCIT treatments in-office since such treatments are billable medical procedures, thus financially rewarding for allergists. SLIT drops are used off-label, and their market penetration has remained significantly lower due to lack of regulatory approvals.
Apart from the injectables demand oral administration, such syrups are also increase in the United States. As incidences of allergies are on the rise in children, oral administration is being opted by the parents as well as healthcare professionals as an alternative to the injectables.
In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 7.4%.
Germany is a leading market for SLIT tablets, largely due to strict regulatory standardization and a patient preference for at-home treatments. The country’s regulatory body, the Paul Ehrlich Institute, enforces rigid allergen extract standardization, ensuring that SLIT tablets and oral formulations meet stringent efficacy and safety requirements.
Unlike the USA, where injections dominate, SLIT tablets have widespread insurance coverage in Germany, making them more accessible. German patients also prefer home-based treatments over frequent clinic visits, which has driven the growth of oral and SLIT tablet options.
Additionally, Germany has one of the most comprehensive pollen monitoring systems in Europe, enabling allergists to recommend highly targeted SLIT treatments based on real-time allergen exposure. Injections (SCIT) are still used but have a smaller market share compared to SLIT tablets, especially for patients seeking non-invasive, long-term treatment options.
India occupies a leading value share in South Asia & Pacific market in 2024 and is expected to grow with a CAGR of 9.6% during the forecasted period.
The allergy immunotherapy market in China is heavily driven by the widespread prevalence of dust mite allergy, thereby seeing a boom in allergy immunotherapies across the region. In contrast, Western markets have pollen allergy-related issues; hence, dust mite sensitization rates are amongst the highest worldwide, thereby causing a higher demand for dust mite-specific medication.
These tablets have gained rapid regulatory approval, significantly boosting their market presence. However, in recent years, SCIT treatments have been expanding in China’s top-tier hospitals, as more specialists recognize their efficacy in long-term allergy management.
The market for oral solutions is also growing, particularly in pediatric cases where children are more likely to tolerate oral formulations over injections. Additionally, China’s humid climate in regions like Guangdong and Shanghai exacerbates dust mite allergies, further fueling demand for targeted SLIT tablet and injection-based immunotherapy treatments.
The section contains information about the leading segments in the industry. Based on product type, injections are expected to account 66.3% of the global share in 2025.
| Product Type | Value Share (2025) |
|---|---|
| Injections | 66.3% |
Injections are the dominant product segment, especially subcutaneous immunotherapy, because they have proven efficacy for a long period and physicians prefer them.
Its quick response against all types of allergic conditions, whether it be bronchial hyper-reactivity, allergic rhinitis, or asthma. Injection, when considered against other methods of treatment, has higher clinical efficacy in serious cases and is often recommended for patients with many allergens or persistent symptoms.
Also, injections, being controlled administration by healthcare professionals, ensure the treatment protocols that reduce the probabilities of improper dosage, which generally is a common limitation with oral and sublingual therapies.
The structured reimbursement system in most developed markets-including the USA and Germany-provides further strength to the trend of injections: insurance providers prefer to cover an in-office procedure.
In addition, allergy clinics and other immunotherapy specialty centers in emerging markets have also contributed to the furtherance of injection-based treatments. Due to continuous improvements in standardized allergen extracts and safety, SCIT remains the most trusted primary form of allergy immunotherapy performed worldwide.
| By Distribution Channel | Value Share (2025) |
|---|---|
| Institutional Sales | 57.8% |
Institutional sales will account for 57.8% of the distribution channel segment in 2025, and exhibit the highest CAGR in the forecast period.
Institutional sales, particularly through hospital pharmacies and medical institutions, hold the largest share in the allergy immunotherapy market, primarily due to the dominance of prescription-based injectable treatments. Since SCIT and other injectable immunotherapies require administration by trained professionals, hospital and institutional pharmacies serve as the primary distribution channels for these treatments.
Prescription drugs, including allergy injections and adjunctive sprays for allergic reactions, are widely available in institutional settings, ensuring regulated distribution and patient compliance.
With injectable immunotherapy presenting higher efficacy and long-term results compared to symptomatic treatments like antihistamines, healthcare providers increasingly recommend them in clinical settings, further solidifying the dominance of institutional sales.
Moreover, government healthcare programs and insurance policies often cover prescription-based allergy treatments within hospitals and specialized clinics, improving patient accessibility and adoption rates.
As global healthcare infrastructure continues to improve, particularly in developing regions, the proliferation of institutional sales channels is expected to sustain the market leadership of injection-based immunotherapy treatments.
Allergic immunotherapy, which is quite a competitive field, is also a market comprised of established players from the pharma industry with a mix of newer biotech firms. Key strategies in competition for this space include product differentiation, research-oriented innovation, and geographical expansion.
Recent Industry Developments in Allergy Immunotherapy Market
In terms of product type, the industry is divided into slit tablets, oral, injections, other product type.
In terms of immunotherapy type, the industry is divided into sublingual immunotherapy (SLIT), subcutaneous immunotherapy (allergy shots), and intralymphatic immunotherapy (ILIT)
In terms of indication, the industry is divided into allergic rhinitis, allergic asthma, food allergy, atopic dermatitis and other indication
In terms of allergen type, the industry is divided into pollens, house dust mites (HDM), mould, animal dander, bee venom, cockroaches/insects and other allergan type
In terms of distribution channel, the industry is segregated into institutional sales and retail sales.
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa (MEA) have been covered in the report.
The global allergy immunotherapy industry is projected to witness CAGR of 7.9% between 2025 and 2035.
The global allergy immunotherapy industry stood at USD 1,840.8 million in 2024.
The global allergy immunotherapy industry is anticipated to reach USD 4,161.9 million by 2035 end.
China is expected to show a CAGR of 9.6% in the assessment period.
The key players operating in the global allergy immunotherapy industry include ALK Abello, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Biomay AG, HollisterStier Allergy, Desentum OY, Anergis, DBV Technologies, Roche, Dermapharm Holdings, and Others.
| Expected Market Value in 2023 | USD 30 billion |
|---|---|
| Projected Market Value in 2033 | USD 50 billion |
| CAGR (2023 to 2033) | 5.2% |
| Expected Market Value (2023) | USD 39.83 Billion |
|---|---|
| Projected Forecast Value (2033) | USD 66.15 Billion |
| Global Growth Rate (2023 to 2033) | 5.2% CAGR |
Explore Therapy Area Insights
View Reports
Allergy Immunotherapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
